Developer docs
API playgroundTry for free, no card

Search company profiles

Innocare

Full company profile

uuid0002ev4

Namestring
Innocare
Legal namestring
诺诚健华医药有限公司
Company typeenum
Public
Founded yearint
2015
Descriptiontext

InnoCare (诺诚健华) is a commercial-stage Chinese biopharmaceutical company founded in 2015 by Dr. Jasmine Cui and structural biologist Professor Shi Yigong, dual-listed on the Hong Kong Stock Exchange (09969.HK) and Shanghai Stock Exchange STAR Market (688428.SH). The company focuses on developing innovative therapies for hematological malignancies and autoimmune diseases, operating an integrated platform that spans drug discovery, clinical development, GMP manufacturing, and direct commercialization. Its commercial portfolio includes three approved products: orelabrutinib (a highly selective covalent BTK inhibitor marketed as Yinuokai/宜诺凯 for CLL/SLL, MCL, and MZL with all indications on China's NRDL), tafasitamab (a CD19 monoclonal antibody licensed from Incyte for DLBCL, marketed as Mingnuokai/明诺凯), and zurletrectinib (a next-generation pan-TRK inhibitor for NTRK fusion-positive solid tumors approved December 2025). The clinical pipeline comprises 13+ candidates across BTK, BCL2, TYK2, IL-17, VAV1 molecular glue degrader, ADC, and bispecific antibody modalities, including several potentially first-in-class assets such as ICP-538 (first VAV1 degrader in clinical trials in China) and ICP-054 (potential first-in-category oral IL-17AA/AF inhibitor).

The company's revenue model combines direct-to-hospital product sales through an in-house commercialization team covering hundreds of hospitals across China, supplemented by out-licensing and milestone payments from international partners. Major 2025 transactions include the Zenas BioPharma deal for autoimmune rights to orelabrutinib (over US$2 billion total value, US$100 million upfront) and the Prolium Bioscience deal for the CD20xCD3 bispecific antibody ICP-B02 (US$520 million total plus equity). Products are sold under China's National Reimbursement Drug List framework, while ex-China commercialization proceeds via partnerships in Singapore, Australia, and broader Asian and US markets through the New Jersey/Boston office. R&D investment of approximately RMB 9.5 billion in 2025 reflects sustained pipeline funding, supported by a substantial cash position and the company's first full year of profitability in 2025 (revenue of RMB 2,375 million, up 135.3% year-on-year, with RMB 644 million net profit).

Short descriptiontext

InnoCare is a commercial-stage Chinese biopharmaceutical company developing innovative therapies for hematological malignancies and autoimmune diseases, with three approved products and 13+ clinical-stage candidates spanning BTK, BCL2, TYK2, ADC, and bispecific antibody modalities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, autoimmune disease therapeutics, BTK inhibitor development, targeted cancer therapy, biopharmaceutical innovation
Industry3 codes
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Oncology Drugs
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model5 records
1Product Sales - Orelabrutinib (Olabrubtinib)
TypeOne Time License
Description

Revenue from sales of approved BTK inhibitor orelabrutinib (brand name Yinuokai/宜诺凯) in China, Singapore, and Australia. Multiple indications covered by national insurance including CLL/SLL, MCL, MZL.

globenewswire.com
2Product Sales - Tafasitamab
TypeOne Time License
Description

Revenue from CD19 monoclonal antibody tafasitamab (brand name Mingnuokai/明诺凯) approved for DLBCL, available in Hong Kong, Bo'ao, and Greater Bay Area.

globenewswire.com
3Product Sales - Zurletrectinib
TypeOne Time License
Description

Revenue from next-generation pan-TRK inhibitor zurletrectinib (ICP-723, brand name Yinuo Xin/宜诺欣) approved for NTRK fusion-positive solid tumors.

globenewswire.com
4Licensing and Milestone Payments
TypeLicensing Royalties
Description

Revenue from out-licensing deals including Zenas BioPharma deal (over US$2 billion total value) for autoimmune pipeline, and Prolium Bioscience deal (US$520 million) for CD20xCD3 bispecific antibody.

globenewswire.com
5Milestone Payments from Collaboration
TypeLicensing Royalties
Description

Upfront payments, development milestones, and royalties from various licensing and collaboration agreements with partners.

globenewswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure, Others
Pricing details1 tier
1National Reimbursement Drug List pricing
ModelSubscriptionBilling cadenceMonthly
Notes

All approved orelabrutinib indications are covered under China's National Medical Insurance Program, reducing drug costs for patients.

globenewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1宜诺凯 (Yinuokai)
Description

Brand name for orelabrutinib (BTK inhibitor) in China

innocarepharma.com
+2 more records
Core offering1 text field

InnoCare is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative small molecule and biologic drugs for the treatment of hematological malignancies and autoimmune diseases. Its three marketed products are orelabrutinib (a BTK inhibitor sold under the Yinuokai brand), tafasitamab (a CD19 monoclonal antibody sold under the Mingnuokai brand), and zurletrectinib (a pan-TRK inhibitor sold under the Yinuoxin brand). The company maintains a pipeline of over 13 clinical-stage drug candidates and operates an integrated platform covering drug discovery, clinical development, manufacturing, and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Orelabrutinib achieved 100% ORR in treatment-naïve CLL/SLL patients with 94.4% 36-month PFS rate at median 38.1 months follow-up
+4 more records
Product overview1 text field

InnoCare (诺诚健华) is a commercial-stage biopharmaceutical company with a comprehensive integrated platform spanning from源头创新 (origin innovation), clinical development, manufacturing to commercialization. The company has developed a robust product portfolio focused on malignant tumors (血液瘤) and autoimmune diseases (自身免疫性疾病). Three products have been approved and launched: Orelabrutinib (BTK inhibitor for hematological malignancies and autoimmune diseases), Tafasitamab (CD19 monoclonal antibody for DLBCL), and Zurletrectinib (pan-TRK inhibitor for NTRK fusion-positive solid tumors). The pipeline includes over 10 clinical-stage innovative drugs covering BTK, BCL2, TYK2, IL-17, VAV1, ADC, and bispecific antibody platforms. The company operates dual A+H listings (688428.SH, 09969.HK) and has achieved its first full year of profitability.

Product and service3 records
1Orelabrutinib (奥布替尼, 宜诺凯, Yinuokai)
CategoryBTK Inhibitor Pharmaceutical Product
Description

A highly selective, covalent, irreversible oral BTK inhibitor developed for treating hematological malignancies (CLL/SLL, MCL, MZL) and autoimmune diseases (ITP, MS, SLE). Features high kinase selectivity reducing off-target effects with better efficacy and safety, achieving 100% BTK target binding with good PK characteristics.

2Tafasitamab (坦昔妥单抗, 明诺凯, Mingnuokai)
CategoryCD19 Monoclonal Antibody Pharmaceutical Product
Description

A CD19-targeted humanized monoclonal antibody with optimized Fc domain that induces B-cell tumor lysis through apoptosis and immune effector mechanisms. Approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide.

3Zurletrectinib (佐来曲替尼, 宜诺欣, Yinuoxin, ICP-723)
CategoryPan-TRK Inhibitor Pharmaceutical Product
Description

A next-generation pan-TRK inhibitor that effectively inhibits TRKA, TRKB, TRKC and overcomes resistance mutations including G595R and G667C. Approved for NTRK fusion-positive solid tumors in adult and pediatric patients.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Phase 1 clinical trial collaboration for oral IL-17AA/AF inhibitor ICP-054 (ZB021) in China. Both companies conducting SAD and MAD studies in healthy volunteers with data expected by end of 2026. Zenas holds ex-Greater China and Southeast Asia rights from original licensing deal.

Strategic tierCore/FlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-10-08
Description

Major licensing agreement where Zenas acquired global development and commercialization rights for orelabrutinib in multiple sclerosis and non-oncology autoimmune indications. Deal includes $100 million upfront plus stock and milestones worth over $2 billion total. InnoCare retains oncology rights globally and autoimmune rights in Greater China and Southeast Asia. Zenas also licensed rights to oral IL-17 AA/AF inhibitor and brain-penetrating TYK2 inhibitor.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-01-20
Description

Licensing deal for CD20xCD3 bispecific antibody ICP-B02 (CM355) in global non-oncology and ex-Asia oncology fields. Deal valued at up to $520 million plus minority equity stake. InnoCare and Keymed to receive upfront, milestones, and tiered royalties on net sales.

Strategic tierCore/FlagshipTypeStrategic or Co-development PartnerAnnounced on2025-01-20
Description

Joint development partnership for CD3xCD20 bispecific antibody ICP-B02 (CM355). Both companies and their joint venture partnered with Prolium for global licensing. Keymed and InnoCare jointly developed the bispecific antibody for hematological malignancies and autoimmune diseases.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Clinical collaboration announced in 2023 milestone timeline. Specific collaboration details not detailed in available sources.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-08-17
Description

Licensing agreement for tafasitamab development and commercialization in Greater China (mainland China, Hong Kong, Macau, Taiwan). InnoCare received $35 million upfront and up to $82.5 million in development, registration and commercialization milestones plus tiered sales royalties. InnoCare holds exclusive commercialization rights in Greater China.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharma whose acalabrutinib is a major second-generation BTK inhibitor competing directly with orelabrutinib in hematological malignancies worldwide. Relevant as the global benchmark for BTK inhibitor commercialization.

TypeDirect peer
Description

US/HK-listed Chinese biopharma with a licensing-driven business model bringing innovative therapies to China. Comparable go-to-market strategy and oncology/autoimmune focus, though Zai Lab is more partner-dependent.

TypeDirect peer
Description

Chinese innovative biopharma with A+H dual listing developing oncology and autoimmune therapeutics. Overlapping therapeutic focus areas and similar China-to-global commercialization trajectory as InnoCare.

TypeDirect peer
Description

Chinese biopharma specializing in bispecific antibodies and immuno-oncology, with similar integrated R&D and commercialization platform. Akeso's bispecific antibody pipeline is directly comparable to InnoCare's CD3xCD20 program (ICP-B02).

TypeDirect peer
Description

BeOne's zanubrutinib (Brukinsa) is a direct BTK inhibitor competitor to orelabrutinib in hematological malignancies. Both are Chinese-founded biopharmas with global commercialization ambitions and dual US/China listings, making BeOne the most directly comparable peer.

6Hansoh Pharmaceutical Group
TypeBroad incumbent
Description

One of China's largest domestic innovative pharmaceutical companies with broad oncology and specialty pharma portfolio. Larger and more diversified than InnoCare, but competes in overlapping therapeutic areas.

TypeEmerging player
Description

Co-developer of CD3xCD20 bispecific antibody ICP-B02 (CM355) with InnoCare. Smaller and more focused than InnoCare but directly relevant as a bispecific antibody specialist and direct collaboration partner.

8Hutchmed (China) Limited
TypeDirect peer
Description

Hong Kong-listed Chinese biopharma with integrated discovery-to-commercialization platform focused on oncology and autoimmune diseases. Similar target indications (solid tumors, hematological cancers) and business model as InnoCare, with comparable scale and pipeline depth.

9Jiangsu Hengrui Pharmaceuticals
TypeBroad incumbent
Description

China's largest innovative pharmaceutical company with extensive oncology pipeline and broad therapeutic coverage. Serves as the dominant domestic incumbent against which Chinese biopharmas like InnoCare compete.

TypeBroad incumbent
Description

First-generation BTK inhibitor ibrutinib established the BTK market in hematology. Relevant as the legacy standard against which InnoCare's selective orelabrutinib differentiates on safety and selectivity.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Innocare

Biopharmaceutical Oncology Drugsinnocarepharma.com

InnoCare is a commercial-stage Chinese biopharmaceutical company developing innovative therapies for hematological malignancies and autoimmune diseases, with three approved products and 13+ clinical-stage candidates spanning BTK, BCL2, TYK2, ADC, and bispecific antibody modalities.

What Innocare does

InnoCare (诺诚健华) is a commercial-stage Chinese biopharmaceutical company founded in 2015 by Dr. Jasmine Cui and structural biologist Professor Shi Yigong, dual-listed on the Hong Kong Stock Exchange (09969.HK) and Shanghai Stock Exchange STAR Market (688428.SH). The company focuses on developing innovative therapies for hematological malignancies and autoimmune diseases, operating an integrated platform that spans drug discovery, clinical development, GMP manufacturing, and direct commercialization. Its commercial portfolio includes three approved products: orelabrutinib (a highly selective covalent BTK inhibitor marketed as Yinuokai/宜诺凯 for CLL/SLL, MCL, and MZL with all indications on China's NRDL), tafasitamab (a CD19 monoclonal antibody licensed from Incyte for DLBCL, marketed as Mingnuokai/明诺凯), and zurletrectinib (a next-generation pan-TRK inhibitor for NTRK fusion-positive solid tumors approved December 2025). The clinical pipeline comprises 13+ candidates across BTK, BCL2, TYK2, IL-17, VAV1 molecular glue degrader, ADC, and bispecific antibody modalities, including several potentially first-in-class assets such as ICP-538 (first VAV1 degrader in clinical trials in China) and ICP-054 (potential first-in-category oral IL-17AA/AF inhibitor).

The company's revenue model combines direct-to-hospital product sales through an in-house commercialization team covering hundreds of hospitals across China, supplemented by out-licensing and milestone payments from international partners. Major 2025 transactions include the Zenas BioPharma deal for autoimmune rights to orelabrutinib (over US$2 billion total value, US$100 million upfront) and the Prolium Bioscience deal for the CD20xCD3 bispecific antibody ICP-B02 (US$520 million total plus equity). Products are sold under China's National Reimbursement Drug List framework, while ex-China commercialization proceeds via partnerships in Singapore, Australia, and broader Asian and US markets through the New Jersey/Boston office. R&D investment of approximately RMB 9.5 billion in 2025 reflects sustained pipeline funding, supported by a substantial cash position and the company's first full year of profitability in 2025 (revenue of RMB 2,375 million, up 135.3% year-on-year, with RMB 644 million net profit).

Innocare firmographics

Firmographics
Name
Innocare
Legal name
诺诚健华医药有限公司
Website
https://innocarepharma.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
InnoCare is a commercial-stage Chinese biopharmaceutical company developing innovative therapies for hematological malignancies and autoimmune diseases, with three approved products and 13+ clinical-stage candidates spanning BTK, BCL2, TYK2, ADC, and bispecific antibody modalities.
Ownership category
akta.pro rank

Innocare industry classification

Industry
Product category
Biopharmaceutical Oncology Drugs
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Oncology drug development
  • Autoimmune disease therapeutics
  • BTK inhibitor development
  • Targeted cancer therapy
  • Biopharmaceutical innovation

Where Innocare is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Offices6 records

Markets served

Innocare business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure, Others

Revenue model

  1. Product Sales - Orelabrutinib (Olabrubtinib): Revenue from sales of approved BTK inhibitor orelabrutinib (brand name Yinuokai/宜诺凯) in China, Singapore, and Australia. Multiple indications covered by national insurance including CLL/SLL, MCL, MZL.
  2. Product Sales - Tafasitamab: Revenue from CD19 monoclonal antibody tafasitamab (brand name Mingnuokai/明诺凯) approved for DLBCL, available in Hong Kong, Bo'ao, and Greater Bay Area.
  3. Product Sales - Zurletrectinib: Revenue from next-generation pan-TRK inhibitor zurletrectinib (ICP-723, brand name Yinuo Xin/宜诺欣) approved for NTRK fusion-positive solid tumors.
  4. Licensing and Milestone Payments: Revenue from out-licensing deals including Zenas BioPharma deal (over US$2 billion total value) for autoimmune pipeline, and Prolium Bioscience deal (US$520 million) for CD20xCD3 bispecific antibody.
  5. Milestone Payments from Collaboration: Upfront payments, development milestones, and royalties from various licensing and collaboration agreements with partners.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyNational Reimbursement Drug List pricing

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Innocare product offering

Product offering

Core offering

InnoCare is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative small molecule and biologic drugs for the treatment of hematological malignancies and autoimmune diseases. Its three marketed products are orelabrutinib (a BTK inhibitor sold under the Yinuokai brand), tafasitamab (a CD19 monoclonal antibody sold under the Mingnuokai brand), and zurletrectinib (a pan-TRK inhibitor sold under the Yinuoxin brand). The company maintains a pipeline of over 13 clinical-stage drug candidates and operates an integrated platform covering drug discovery, clinical development, manufacturing, and commercialization.

Product overview

InnoCare (诺诚健华) is a commercial-stage biopharmaceutical company with a comprehensive integrated platform spanning from源头创新 (origin innovation), clinical development, manufacturing to commercialization. The company has developed a robust product portfolio focused on malignant tumors (血液瘤) and autoimmune diseases (自身免疫性疾病). Three products have been approved and launched: Orelabrutinib (BTK inhibitor for hematological malignancies and autoimmune diseases), Tafasitamab (CD19 monoclonal antibody for DLBCL), and Zurletrectinib (pan-TRK inhibitor for NTRK fusion-positive solid tumors). The pipeline includes over 10 clinical-stage innovative drugs covering BTK, BCL2, TYK2, IL-17, VAV1, ADC, and bispecific antibody platforms. The company operates dual A+H listings (688428.SH, 09969.HK) and has achieved its first full year of profitability.

Differentiator

Problem solved

Functional benefit

Brands

  • 宜诺凯 (Yinuokai): Brand name for orelabrutinib (BTK inhibitor) in China
  • 明诺凯 (Mingnuokai)
  • 宜诺欣 (Yinuoxin)

Products and services

  • Orelabrutinib (奥布替尼, 宜诺凯, Yinuokai) A highly selective, covalent, irreversible oral BTK inhibitor developed for treating hematological malignancies (CLL/SLL, MCL, MZL) and autoimmune diseases (ITP, MS, SLE). Features high kinase selectivity reducing off-target effects with better efficacy and safety, achieving 100% BTK target binding with good PK characteristics.
  • Tafasitamab (坦昔妥单抗, 明诺凯, Mingnuokai) A CD19-targeted humanized monoclonal antibody with optimized Fc domain that induces B-cell tumor lysis through apoptosis and immune effector mechanisms. Approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in combination with lenalidomide.
  • Zurletrectinib (佐来曲替尼, 宜诺欣, Yinuoxin, ICP-723) A next-generation pan-TRK inhibitor that effectively inhibits TRKA, TRKB, TRKC and overcomes resistance mutations including G595R and G667C. Approved for NTRK fusion-positive solid tumors in adult and pediatric patients.

Quantifiable outcome

  • Orelabrutinib achieved 100% ORR in treatment-naïve CLL/SLL patients with 94.4% 36-month PFS rate at median 38.1 months follow-up
  • +4 more outcomes

Companies that use Innocare

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Innocare technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Innocare partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major, core/flagship and minor.

  • Zenas BioPharma (ZB021/ICP-054 partnership)majorStrategic or Co-development Partner · 13 May 2026Phase 1 clinical trial collaboration for oral IL-17AA/AF inhibitor ICP-054 (ZB021) in China. Both companies conducting SAD and MAD studies in healthy volunteers with data expected by end of 2026. Zenas holds ex-Greater China and Southeast Asia rights from original licensing deal.
  • Zenas BioPharmacore/flagshipOEM/ Whitelabel/ Licensing Partner · 8 October 2025Major licensing agreement where Zenas acquired global development and commercialization rights for orelabrutinib in multiple sclerosis and non-oncology autoimmune indications. Deal includes $100 million upfront plus stock and milestones worth over $2 billion total. InnoCare retains oncology rights globally and autoimmune rights in Greater China and Southeast Asia. Zenas also licensed rights to oral IL-17 AA/AF inhibitor and brain-penetrating TYK2 inhibitor.
  • Prolium BiosciencemajorOEM/ Whitelabel/ Licensing Partner · 20 January 2025Licensing deal for CD20xCD3 bispecific antibody ICP-B02 (CM355) in global non-oncology and ex-Asia oncology fields. Deal valued at up to $520 million plus minority equity stake. InnoCare and Keymed to receive upfront, milestones, and tiered royalties on net sales.
  • Keymed Biosciences (康诺亚)core/flagshipStrategic or Co-development Partner · 20 January 2025Joint development partnership for CD3xCD20 bispecific antibody ICP-B02 (CM355). Both companies and their joint venture partnered with Prolium for global licensing. Keymed and InnoCare jointly developed the bispecific antibody for hematological malignancies and autoimmune diseases.
  • ArriVent BiopharmaminorStrategic or Co-development Partner · 1 January 2023Clinical collaboration announced in 2023 milestone timeline. Specific collaboration details not detailed in available sources.
  • IncytemajorOEM/ Whitelabel/ Licensing Partner · 17 August 2021Licensing agreement for tafasitamab development and commercialization in Greater China (mainland China, Hong Kong, Macau, Taiwan). InnoCare received $35 million upfront and up to $82.5 million in development, registration and commercialization milestones plus tiered sales royalties. InnoCare holds exclusive commercialization rights in Greater China.

Scale indicators11 records

Recent moves9 records

Expansion highlights7 records

Innocare competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca (Calquence/acalabrutinib): Global pharma whose acalabrutinib is a major second-generation BTK inhibitor competing directly with orelabrutinib in hematological malignancies worldwide. Relevant as the global benchmark for BTK inhibitor commercialization.
  • Hansoh Pharmaceutical Group: One of China's largest domestic innovative pharmaceutical companies with broad oncology and specialty pharma portfolio. Larger and more diversified than InnoCare, but competes in overlapping therapeutic areas.
  • Jiangsu Hengrui Pharmaceuticals: China's largest innovative pharmaceutical company with extensive oncology pipeline and broad therapeutic coverage. Serves as the dominant domestic incumbent against which Chinese biopharmas like InnoCare compete.
  • AbbVie / Johnson & Johnson (Imbruvica/ibrutinib): First-generation BTK inhibitor ibrutinib established the BTK market in hematology. Relevant as the legacy standard against which InnoCare's selective orelabrutinib differentiates on safety and selectivity.

Direct peers

  • Zai Lab Limited: US/HK-listed Chinese biopharma with a licensing-driven business model bringing innovative therapies to China. Comparable go-to-market strategy and oncology/autoimmune focus, though Zai Lab is more partner-dependent.
  • Shanghai Junshi Biosciences: Chinese innovative biopharma with A+H dual listing developing oncology and autoimmune therapeutics. Overlapping therapeutic focus areas and similar China-to-global commercialization trajectory as InnoCare.
  • Akeso, Inc. Chinese biopharma specializing in bispecific antibodies and immuno-oncology, with similar integrated R&D and commercialization platform. Akeso's bispecific antibody pipeline is directly comparable to InnoCare's CD3xCD20 program (ICP-B02).
  • BeOne Medicines (formerly BeiGene): BeOne's zanubrutinib (Brukinsa) is a direct BTK inhibitor competitor to orelabrutinib in hematological malignancies. Both are Chinese-founded biopharmas with global commercialization ambitions and dual US/China listings, making BeOne the most directly comparable peer.
  • Hutchmed (China) Limited: Hong Kong-listed Chinese biopharma with integrated discovery-to-commercialization platform focused on oncology and autoimmune diseases. Similar target indications (solid tumors, hematological cancers) and business model as InnoCare, with comparable scale and pipeline depth.

Emerging players

  • Keymed Biosciences: Co-developer of CD3xCD20 bispecific antibody ICP-B02 (CM355) with InnoCare. Smaller and more focused than InnoCare but directly relevant as a bispecific antibody specialist and direct collaboration partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Innocare social profiles

Digital presence

Innocare financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Innocare leadership team

Management profile

Number of profiles

Profiles18 records

Innocare subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Innocare funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Innocare M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innocare

What does Innocare do?

InnoCare is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative small molecule and biologic drugs for the treatment of hematological malignancies and autoimmune diseases. Its three marketed products are orelabrutinib (a BTK inhibitor sold under the Yinuokai brand), tafasitamab (a CD19 monoclonal antibody sold under the Mingnuokai brand), and zurletrectinib (a pan-TRK inhibitor sold under the Yinuoxin brand). The company maintains a pipeline of over 13 clinical-stage drug candidates and operates an integrated platform covering drug discovery, clinical development, manufacturing, and commercialization.

Is Innocare a public or private company?

Innocare is a public company. It is classified as public and is currently operating.

When was Innocare founded?

Innocare was founded in 2015. It employs 101 to 250 people.

Where is Innocare based?

Innocare is headquartered in Beijing, China, in the Asia region.

How does Innocare make money?

Five revenue lines are on record. Product Sales - Orelabrutinib (Olabrubtinib) is the primary driver. The others are product Sales - Tafasitamab, product Sales - Zurletrectinib, licensing and Milestone Payments and milestone Payments from Collaboration.

Who are Innocare's main competitors?

Broad incumbents on record are AstraZeneca (Calquence/acalabrutinib), Hansoh Pharmaceutical Group, Jiangsu Hengrui Pharmaceuticals and AbbVie / Johnson & Johnson (Imbruvica/ibrutinib). Direct peers are Zai Lab Limited, Shanghai Junshi Biosciences, Akeso, Inc., BeOne Medicines (formerly BeiGene) and Hutchmed (China) Limited. Keymed Biosciences is listed as an emerging player.

Does Innocare have an API?

No public API is recorded for Innocare.

What industry is Innocare in?

Innocare's product category is Biopharmaceutical Oncology Drugs. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MoomooEU approval for senaparib marks a critical step toward global commercialization, accelerating the realization of its innovative value and making Impmed Biopharma-B (07630) a key investment holding.InnoCare Pharma announced EU approval of its PARP inhibitor senaparib for maintenance therapy in advanced ovarian, fallopian tube, and peritoneal cancers. The drug, approved in China last January, is now available in multiple regions, and the company licensed it to Pharmanovia for global commercialization. The approval marks a key step toward global commercialization and stable recurring cash flow.MoomooHong Kong Stock Market Movers | Imunon-B (07630) opens nearly 15% higher as Senaparib receives EU marketing approval; global clinical development actively advancingInnoCare Pharma-B's stock opened nearly 15% higher after its drug senaparib received EU marketing approval for ovarian cancer maintenance therapy. The approval, granted by the European Commission, makes it the first China-originated PARP inhibitor approved for first-line maintenance across all patient populations. The company is advancing global clinical and regulatory development.MoomooHK Stock Market Watch | Imeik-B (07630) surges over 10% in late trading; EU marketing authorization for senaparib expected to be approved this monthInnoCare Pharma-B rose over 10% in late trading, up 6.02% to HK$8.895. The company announced a HK$100 million share repurchase plan, and its EU marketing authorization for senaparib is expected to be approved this month after a positive CHMP opinion in September.Business & FinancialInnocare Announces First Patient Dosed In Clinical Trial Of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 In ChinaInnoCare Pharma announced the first patient dosed in the Phase I trial of ICP-B381, a bispecific ADC targeting PSMA and STEAP1 for solid tumors including prostate cancer. The ADC outperformed single-target ADCs in preclinical studies and is the company's first bispecific ADC. The company plans to accelerate development to bring the treatment to patients.The future of tradingInnoCare Announces First Patient Dosed in Clinical Trial of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 in ChinaInnoCare Pharma announced the first patient dosed in the Phase I trial of ICP-B381, a bispecific ADC targeting PSMA and STEAP1 for solid tumors including prostate cancer. The drug outperformed single-target ADCs in preclinical studies and is the first bispecific ADC targeting both targets, with no such product approved globally.The future of tradingInnoCare Doses First Patient in Phase I Trial of Cancer Drug ICP-B381 in ChinaInnoCare Pharma dosed the first patient in a Phase I trial of ICP-B381, a bispecific antibody-drug conjugate targeting PSMA and STEAP1, for solid tumors including prostate cancer in China. Preclinical results showed stronger antitumor activity than single-target treatments at the same dose, with favorable tolerability. No such bispecific ADC has global marketing approval.FinancialContent Business PageInnoCare Announces First Patient Dosed in Clinical Trial of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 in ChinaInnoCare Pharma announced the first patient dosed in the Phase I trial of ICP-B381, a bispecific ADC targeting PSMA and STEAP1 for solid tumors including prostate cancer. The ADC outperformed single-target ADCs in preclinical studies and is the first of its kind globally. The company plans to accelerate development to bring the treatment to patients.TradingViewInnoCare Announces First Patient Dosed in Clinical Trial of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 in ChinaInnoCare Pharma announced the first patient dosed in its Phase I trial of ICP-B381, a bispecific ADC targeting PSMA and STEAP1 for solid tumors including prostate cancer. The ADC outperformed single-target ADCs in preclinical studies and is the first of its kind globally. The company plans to accelerate development to bring the treatment to patients.TradingViewInnoCare Pharma Doses First Patient in ICP-B381 Phase I TrialInnoCare Pharma dosed the first patient in China in a Phase I trial of ICP-B381, a bispecific ADC targeting PSMA and STEAP1 for solid tumors. The release provides no clinical efficacy results, and the next catalyst would be reported human safety and efficacy data.GlobeNewswireInnoCare Announces First Patient Dosed in Clinical Trial of Novel PSMA/ STEAP1 Bispecific ADC ICP-B381 in ChinaInnoCare Pharma announced the first patient dosed in the Phase I trial of ICP-B381, a bispecific ADC targeting PSMA and STEAP1 for solid tumors including prostate cancer. The ADC outperformed single-target ADCs in preclinical studies and is the first of its kind in development. The company plans to accelerate development to bring the treatment to patients.